![John Townsend](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 30/09/2026
John W.
Townsend is Chief Financial Officer at Unicycive Therapeutics, Inc. since 2021.
Formerly, Mr. Townsend was Chief Accounting Officer at Plus Therapeutics, Inc. in 2015.
From 2017 to 2020, Mr. Townsend was Chief Accounting Officer & Controller at Guardion Health Sciences, Inc. Mr. Townsend completed an undergraduate degree at San Diego State University in 1993.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 14/05/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| UNICYCIVE THERAPEUTICS, INC. | Director Financiero/CFO | 01/03/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| GUARDION HEALTH SCIENCES, INC. | Comptroller/Controller/Auditor | 02/09/2020 |
| CERENOME, INC. | Comptroller/Controller/Auditor | 30/06/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
San Diego State University
 San Diego State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Plus Therapeutics, Inc.
 Plus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops radio therapeutics products | Health Technology |
Guardion Health Sciences, Inc.
 Guardion Health Sciences, Inc. Pharmaceuticals: OtherHealth Technology Develops and distributes food & dietary supplements | Health Technology |
Unicycive Therapeutics, Inc.
 Unicycive Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic drugs to treat kidney diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
